9.21
+0.05(+0.55%)
Currency In USD
| Previous Close | 9.16 |
| Open | 9.25 |
| Day High | 9.55 |
| Day Low | 9.09 |
| 52-Week High | 29.61 |
| 52-Week Low | 5.9 |
| Volume | 3.42M |
| Average Volume | 2.14M |
| Market Cap | 676.18M |
| PE | -9.12 |
| EPS | -1.01 |
| Moving Average 50 Days | 8.34 |
| Moving Average 200 Days | 9.87 |
| Change | 0.05 |
If you invested $1000 in Arvinas, Inc. (ARVN) since IPO date, it would be worth $573.83 as of October 26, 2025 at a share price of $9.21. Whereas If you bought $1000 worth of Arvinas, Inc. (ARVN) shares 5 years ago, it would be worth $437.32 as of October 26, 2025 at a share price of $9.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 24, 2025 8:00 PM GMT
– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal, and lung cancer – – Data underscore differentiation of ARV-806 from other G12D targeting ag
Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
GlobeNewswire Inc.
Oct 22, 2025 8:00 PM GMT
NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preclinical data for ARV-806, a PROTA
Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
GlobeNewswire Inc.
Oct 20, 2025 8:15 AM GMT
– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant – NEW HAVEN, Conn.,